There is no established standard dose for this case; it is advisable to consult a professional.
Double-blind, placebo-controlled phase II trial: a combination of metabolic activators (which improves the use of fat by mitochondria and reduces oxidative stress) improved cognition in patients with Alzheimer's disease. Promising; needs to be confirmed in larger trials.
View the study (study) →Information, not medical advice. Scientific evidence reflects the quality of the studies.